Novem Group Has $969,000 Holdings in DexCom, Inc. (NASDAQ:DXCM)

Novem Group lifted its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 30.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 14,184 shares of the medical device company's stock after purchasing an additional 3,321 shares during the period. Novem Group's holdings in DexCom were worth $969,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Private Trust Co. NA raised its stake in DexCom by 99.4% during the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock valued at $46,000 after purchasing an additional 335 shares during the last quarter. Pinnacle Financial Partners Inc increased its holdings in shares of DexCom by 20.3% during the 1st quarter. Pinnacle Financial Partners Inc now owns 55,735 shares of the medical device company's stock worth $3,815,000 after purchasing an additional 9,398 shares during the period. Horizon Financial Services LLC acquired a new position in shares of DexCom during the first quarter valued at about $56,000. DAVENPORT & Co LLC lifted its stake in shares of DexCom by 17.2% in the first quarter. DAVENPORT & Co LLC now owns 45,136 shares of the medical device company's stock valued at $3,082,000 after buying an additional 6,615 shares during the period. Finally, Sumitomo Mitsui DS Asset Management Company Ltd grew its position in DexCom by 1.5% during the first quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 47,984 shares of the medical device company's stock worth $3,277,000 after buying an additional 721 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at DexCom

In other news, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction on Monday, June 16th. The stock was sold at an average price of $83.13, for a total value of $228,607.50. Following the transaction, the director owned 56,621 shares of the company's stock, valued at $4,706,903.73. This represents a 4.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Michael Jon Brown sold 500 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $82.80, for a total value of $41,400.00. Following the completion of the sale, the executive vice president owned 95,102 shares of the company's stock, valued at $7,874,445.60. This represents a 0.52% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 27,190 shares of company stock worth $2,281,732 over the last quarter. 0.32% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

DXCM has been the subject of several recent research reports. Barclays upped their price target on DexCom from $90.00 to $93.00 and gave the company an "equal weight" rating in a report on Monday, May 5th. Citigroup reissued a "buy" rating and set a $102.00 price objective (up from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Robert W. Baird lowered their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Wall Street Zen cut shares of DexCom from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. Finally, Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Five research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $98.50.

DexCom Trading Down 1.0%

Shares of DXCM traded down $0.85 during trading hours on Friday, hitting $82.73. 1,841,055 shares of the stock traded hands, compared to its average volume of 4,400,961. The business has a fifty day moving average of $83.03 and a 200-day moving average of $79.76. The firm has a market capitalization of $32.44 billion, a PE ratio of 61.74, a price-to-earnings-growth ratio of 1.78 and a beta of 1.44. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $117.19. The company has a current ratio of 1.50, a quick ratio of 1.32 and a debt-to-equity ratio of 0.55.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The business had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same quarter in the previous year, the company posted $0.32 earnings per share. The business's revenue for the quarter was up 12.5% on a year-over-year basis. Analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.